Cambrex May Raise Bulk Prices To Offset Loss Of Mylan Royalties
Executive Summary
Cambrex may raise the price of methyclothiazide, lorazepam and clorazepate active pharmaceutical ingredients to offset the loss of royalty revenue that it is no longer receiving from Mylan, CEO James Mack told an investor teleconference Jan. 27.